Recent Updates
Recently added Catalysts

Allogeneic NK Cells

Phase 2

Refractory Rheumatoid Arthritis (RA) | Small molecule | Rare Disease |Artiva Biotherapeutics, Inc.|Last Updated: May 22, 2026

Success Probability
Subscribe to view
Market & Valuation
Subscribe to view
Trial Design
UNCONTROLLED
Total Trials1
Total Enrollment90
FDA Designations
No designations recorded
Clinical trial landscape

Allogeneic NK Cells · 1 trial · 9 indications

Phase 2 1
NCT06991114AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.Refractory Rheumatoid Arthritis (RA)
RECRUITING90 Analytics
PHASE2RECRUITING
AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
Refractory Rheumatoid Arthritis (RA)
NCT0699111490
Unlock trial analytics
Study Endpoints
Primary Endpoints
Safety
From enrollment until the end of treatment at Week 104.

Dose Limiting toxicities assessed in a incrementing dose design.

Secondary Endpoints
Rheumatoid Arthritis: Disease Activity Score 28 (DAS28 - ESR)
Week 52
Sjögren's Disease: Improvement in Clinical EULAR Sjögren's Syndrome Disease Activity Index (ClinESSDAI)
Week 52
Idiopathic Inflammatory Myopathies: Total Improvement Score (TIS)
Week 52
Unlock Study Endpoints
Study Design & Arms
AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
AlloNKEXPERIMENTALAlloNK, dosed after a conditioning regimen, combined with Rituximab.
Interventions
NameTypeDescription
Allogeneic NK CellsDRUGAlloNK, dosed after a conditioning regimen, combined with Rituximab.
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites52

For Subjects with Refractory Rheumatoid Arthritis (RA): * Documented diagnosis of RA, meeting the 2010 ACR/EULAR classification criteria. * Rheumatoid Factor (RF) or Anti Citrullinated Protein Antibody (ACPA) positive. * High-sensitivity C-reactive protein (hs-CRP) \> 3 mg/L or Erythrocyte Sediment...

Countries:United StatesBrazilBulgariaFranceGermanyItalyPolandPortugalRomaniaSerbiaSpain
Unlock Eligibility Criteria
Competitive Landscape -Rheumatoid Arthritis 95 trials (matched to "Refractory Rheumatoid Arthritis (RA)")

Top 20 of 28 competitors

CompanyTickerTrialsLead PhaseDrugs
AbbVie, Inc.ABBV6PHASE3Upadacitinib, Adalimumab
Bristol-Myers Squibb CompanyBMY6PHASE3Abatacept, Adalimumab, Methotrexate
Eli Lilly and CompanyLLY4PHASE3Baricitinib, Tocilizumab
Johnson & JohnsonJNJ2PHASE3Ustekinumab, Guselkumab
AstraZeneca PLCAZN4PHASE2AZD1163
Novartis AG Sponsored ADRNVS4PHASE2VAY736 PFS, VAY736 AI
Merck & Co., Inc.MRK2PHASE2Tulisokibart, Methotrexate
AnaptysBio, Inc.ANAB1PHASE2Rosnilimab
Spyre Therapeutics, IncSYRE1PHASE2SPY002-072
Sanofi SA Sponsored ADRSNY2PHASE2Sarilumab SAR153191
Immunovant IncIMVT1PHASE2IMVT-1402
XBiotech, Inc.XBIT1PHASE2Natrunix, Methotrexate
Amgen Inc.AMGN1PHASE2Inebilizumab, Blinatumomab
Artiva Biotherapeutics, Inc.ARTV2PHASE2Allogeneic NK Cells
Gilead Sciences, Inc.GILD1PHASE1GS-0151
Zenas BioPharma, Inc.ZBIO1PHASE1ZB002
Stryker CorporationSYK5N/AUndisclosed
Zimmer Biomet Holdings, Inc.ZBH29N/AUndisclosed
Sonoma Pharmaceuticals, Inc.SNOA2PHASE1SBT777101
Adicet Bio IncACET1PHASE1ADI-001, Fludarabine, Cyclophosphamide
Unlock Competitive Intelligence
Recent Changes (Last 90 Days)
LOWMay 26, 2026NCT06991114primaryCompletionDate: changed
LOWMay 24, 2026NCT06991114studyFirstPostDate: changed